Why Is CULLINAN THERAPEUTIC (CGEM) Stock Down Today?

Cullinan Therapeutics (CGEM) fell 19.01% to $17.55 on Thursday, marking one of the largest declines in the biotech sector. The stock opened at $21.75 but quickly moved lower, reaching a session low of $17.53 before closing at that level. The selloff appears to be part of a broader market rotation away from biotech stocks, with the company’s recent pipeline announcements and ongoing trial data failing to offset investor caution.

What Happened

CGEM’s sharp decline came amid a broader slump in biotech stocks, with the company among the most heavily affected. Despite a planned interim analysis of its phase 3 REZILIENT3 trial being selected for presentation at the IASLC 2026 World Conference on Lung Cancer, the market reacted negatively. The stock’s drop followed recent insider sales by the Chief Scientific Officer, Jennifer Michaelson, who has sold shares on three occasions over the past two months. The company also announced its CEO and CMO will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Sept. 24, but the event did not provide immediate support to the stock.

What The Data Shows

CGEM’s intraday session showed a steep decline, with volume reaching 0.8 million shares, or 0.9 times the 3-month average. The stock has fallen 9.5% over the past eight sessions, from $20.59 to $18.63, and printed 83 fresh 52-week lows on Sept. 23. The stock is currently trading near the lower end of its 52-week range of $5.68 to $23.19. Despite recent positive developments in its pipeline, including the zipalertinib combo clearing a key phase 3 hurdle, the stock remains unprofitable with an EPS TTM of -3.47 and a beta of 0.02.

What To Watch

Investors should continue to monitor the planned fireside chat on Sept. 24 for further insights into CGEM’s pipeline strategy. The company’s upcoming presentation at the IASLC conference may also provide clarity on its phase 3 trial progress.